Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Dual molecular targeted therapy for mTOR and PI3K may be a promising therapeutic strategy in the specific population of patients with lung cancer with LKB1 loss.
|
30825612 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutations in EGFR, KRAS, BRAF, and PIK3CA genes are widely analyzed in solid tumors such as lung cancer, colorectal cancer, breast cancer, and melanoma.
|
29304903 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, targeting the PI3K pathway may be a potential therapeutic strategy that prevents the structural skeletal damage associated with bone metastasis of lung cancer.
|
30896825 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA OECC promotes cell proliferation and metastasis through the PI3K/Akt/mTOR signaling pathway in human lung cancer.
|
31452780 |
2019 |
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Consistently, DOK7V1 overexpression in lung cancer cells suppressed the phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathways, but activated the focal adhesion kinase (FAK)/paxillin signaling pathway.
|
30431081 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
The phosphoinositide 3-kinase (PI3K)/AKT/mechanistic target of rapamycin (mTOR) signaling has been shown to contribute to tumorigenesis, tumor progression, and resistance to therapy in most human cancer types, including lung cancer.
|
31262325 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our studies suggest that miR-183-5p may function as a tumor suppressor in lung cancer via the miR-183-5p/PIK3CA regulatory axis and identify a potentially effective therapeutic strategy for lung cancer.
|
30528264 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Co-mutations in <i>TP53</i> and the <i>PI3K/AKT/mTOR</i> pathway confer additional resistance to anti-HER2 treatments in lung cancer.
|
31748336 |
2019 |
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Finally, we identified that the PI3K-AKT and epilthelial-mesenchymal transition (EMT) signaling pathways were inhibited by miR-3666 overexpression in lung cancer cells.
|
30481052 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Inotilone from Inonotus linteus suppresses lung cancer metastasis in vitro and in vivo through ROS-mediated PI3K/AKT/MAPK signaling pathways.
|
30787353 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, Aclidinium Bromide suppressed the PI3K/AKT signaling pathway in lung cancer A549 cells.
|
31128006 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Furthermore, cotreatment with sesamin and CAY10404 markedly reduced the levels of phosphorylated protein kinase B (pAkt) and phosoinositide 3 kinase (PI3K) in three lung cancer cell lines.
|
30365050 |
2019 |
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
MicroRNA-374b accelerates the development of lung cancer through downregulating PTEN expression via activating PI3K/Akt pathway.
|
30779080 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
All of these results suggested that the lncRNA FER1L4 suppressed cell proliferation and metastasis by inhibiting the PI3K/Akt signaling pathway in lung cancer.
|
31115514 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.
|
31100334 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
To date, PI3K inhibitors have not been approved for lung cancer.
|
31337981 |
2019 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Methyl nonanoate, (R)-citronellol, cis-carveol (L-carveol), 3-methyl-Cyclohexanone, 4-carene and thujopsene were finally screened for PI3K targeted anti-cancer therapies which may find direct application as inhalers or sprays against lung cancer as these compounds are highly volatile.
|
28356026 |
2018 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
The effect of paclitaxel combined with lobaplatin on the sensitivity of lung cancer cell line NCI-H446 through influencing the phosphatidylinositol 3-kinase (PI3K)/Akt pathway was investigated.
|
29616103 |
2018 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
The mechanism may involve of PI3K/AKT signaling pathways in A549 cells, which may a potential therapeutic target for the treatment of lung cancer.
|
30344755 |
2018 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
RAS signaling through PI3K is necessary for normal lymphatic vasculature development and for RAS-induced transformation in vitro and in vivo, especially in lung cancer, where it is essential for tumor initiation and necessary for tumor maintenance.
|
28847905 |
2018 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Fibroblast activation protein-α promotes the growth and migration of lung cancer cells via the PI3K and sonic hedgehog pathways.
|
29115573 |
2018 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results suggest that 27HC promotes lung cancer cell proliferation via ERβ and PI3K-Akt signaling.
|
30190703 |
2018 |
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings demonstrate that PI3K/AKT/YY1 is involved in the regulation of lung cancer cell behavior induced by IL‑13, and miR‑29a represents a promising therapeutic target.
|
29620222 |
2018 |
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
|
29516506 |
2018 |
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that regulation of JNK/ P38/PI3K by TGF-β1 led to down expression of NMII-A which promoted EMT and lung cancer metastasis.
|
28782471 |
2018 |